Skip to main content
. 2008 Sep 11;3(9):e3193. doi: 10.1371/journal.pone.0003193

Figure 9. Effectiveness of vaccines given different levels of mass vaccination coverage when delivered via EPI with community wide campaigns for different transmission settings (BSV (a–c), BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/PEV (m–o) and BSV/TBV (p–r)).

Figure 9

Results obtained assuming an initial vaccine efficacy of 52%, a vaccine half-life of 10 years and homogeneity value of 10.